Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Increased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis
Agata Radwanska, … , Cory M. Hogaboam, Lynne A. Murray
Agata Radwanska, … , Cory M. Hogaboam, Lynne A. Murray
Published August 22, 2022
Citation Information: JCI Insight. 2022;7(16):e153058. https://doi.org/10.1172/jci.insight.153058.
View: Text | PDF
Research Article Cell biology Pulmonology

Increased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis

  • Text
  • PDF
Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic disease of unmet medical need. It is characterized by formation of scar tissue leading to a progressive and irreversible decline in lung function. IPF is associated with repeated injury, which may alter the composition of the extracellular matrix (ECM). Here, we demonstrate that IPF patient–derived pulmonary ECM drives profibrotic response in normal human lung fibroblasts (NHLF) in a 3D spheroid assay. Next, we reveal distinct alterations in composition of the diseased ECM, identifying potentially novel associations with IPF. Growth differentiation factor 15 (GDF15) was identified among the most significantly upregulated proteins in the IPF lung–derived ECM. In vivo, GDF15 neutralization in a bleomycin-induced lung fibrosis model led to significantly less fibrosis. In vitro, recombinant GDF15 (rGDF15) stimulated α smooth muscle actin (αSMA) expression in NHLF, and this was mediated by the activin receptor-like kinase 5 (ALK5) receptor. Furthermore, in the presence of rGDF15, the migration of NHLF in collagen gel was reduced. In addition, we observed a cell type–dependent effect of GDF15 on the expression of cell senescence markers. Our data suggest that GDF15 mediates lung fibrosis through fibroblast activation and differentiation, implicating a potential direct role of this matrix-associated cytokine in promoting aberrant cell responses in disease.

Authors

Agata Radwanska, Christopher Travis Cottage, Antonio Piras, Catherine Overed-Sayer, Carina Sihlbom, Ramachandramouli Budida, Catherine Wrench, Jane Connor, Susan Monkley, Petra Hazon, Holger Schluter, Matthew J. Thomas, Cory M. Hogaboam, Lynne A. Murray

×

Figure 6

GDF15 promotes profibrotic responses in lung fibroblasts.

Options: View larger image (or click on image) Download as PowerPoint
GDF15 promotes profibrotic responses in lung fibroblasts.
(A) TMLC repor...
(A) TMLC reporter cells were stimulated with rGDF15 or TGF-β for 24 hours, and luminescence corresponding to PAI1 receptor activity was measured; n = 3 biological replicates. (B) NHLF were incubated for 48 hours with rGDF15 alone, and/or with 0.5 ng/mL of TGF-β, or with SB525334 inhibitor. Next, αSMA and nuclei were immunofluorescence labeled, and the percentage of αSMA+ cells was quantified using MetaXpress High Content Image Analysis Software. Data are expressed as mean ± SD of n = 3 biological replicates. (C and D) The expression of COL1A1 (C) and COL3A1 (D) in rGDF15-stimulated NHLF was calculated after the normalization to GAPDH housekeeping gene expression and compared with untreated cells, shown as 2–ΔΔCT (fold change) and presented using box-and-whisker plots, with the line in the middle plotted at the median. *P < 0.05 and ****P < 0.000 by 1-way ANOVA; n = 4 biological replicates.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts